{"doi":"10.17615/02e0-mp93","title":"Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development","abstract":"Liver damage and fibrosis are precursors of hepatocellular carcinoma (HCC). In HCC patients, sorafenib—a multikinase inhibitor drug—has been reported to exert anti-fibrotic activity. However, incomplete inhibition of RAF activity by sorafenib may also induce paradoxical activation of the mitogen-activated protein kinase (MAPK) pathway in malignant cells. The consequence of this effect in non-malignant disease (hepatic fibrosis) remains unknown. This study aimed to examine the effects of sorafenib on activated hepatic stellate cells (HSCs), and develop effective therapeutic approaches to treat liver fibrosis and prevent cancer development.","journal":"UNC Libraries","year":2020,"id":117319,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9488,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2020-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":547642,"name":"Ling-Hsuan Chen","orcid":null,"position":1,"is_corresponding":false},{"id":547643,"name":"Anthony Y. Wu","orcid":null,"position":2,"is_corresponding":false},{"id":546895,"name":"Dongyu Gao","orcid":"0000-0002-4864-5145","position":3,"is_corresponding":false},{"id":547644,"name":"Tsaiyu Chiang","orcid":null,"position":4,"is_corresponding":false},{"id":546896,"name":"Chih-Chun Chang","orcid":"0000-0002-2891-8804","position":5,"is_corresponding":false},{"id":266751,"name":"Charles Pin‐Kuang Lai","orcid":"0000-0001-8050-7060","position":6,"is_corresponding":false},{"id":238100,"name":"Dan G. Duda","orcid":"0000-0001-7065-8797","position":7,"is_corresponding":false},{"id":546897,"name":"Jane Wang","orcid":"0000-0003-3705-3993","position":8,"is_corresponding":false},{"id":547645,"name":"Ja-An Lin","orcid":null,"position":9,"is_corresponding":false},{"id":498947,"name":"Yunching Chen","orcid":"0000-0001-6228-5169","position":10,"is_corresponding":false},{"id":546898,"name":"Pei-Ru Jin","orcid":"0000-0002-3062-1540","position":11,"is_corresponding":false},{"id":547646,"name":"Ya-Chi Liu","orcid":null,"position":12,"is_corresponding":false},{"id":547647,"name":"Ting-Lun Ho","orcid":null,"position":13,"is_corresponding":false},{"id":546899,"name":"Hui‐Teng Cheng","orcid":"0000-0003-1544-7473","position":14,"is_corresponding":false},{"id":546900,"name":"Yun‐Chieh Sung","orcid":"0000-0001-7525-0694","position":15,"is_corresponding":false},{"id":546901,"name":"Po‐Han Chao","orcid":"0000-0002-0350-4963","position":16,"is_corresponding":false},{"id":547641,"name":"Ts-Ting Lin","orcid":null,"position":0,"is_corresponding":true}],"reference_count":0,"raw_metadata":null,"created_at":"2026-07-18T23:13:51.309289Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}